ASN009

ASN009 is an investigational **oral small-molecule antagonist of the purinergic P2X3 ion channel** being developed by **Asana BioSciences**. P2X3 is an ATP-gated sensory neuronal ion channel implicated in afferent signaling involved in cough, pain, urologic disorders, and other hypersensitivity conditions. Based on the provided information, ASN009 was described as a **highly selective P2X3 antagonist** with **preclinical proof-of-concept in a rodent cough model**, and it remained in **preclinical development with IND-enabling studies in progress** during the 2019 to 2021 period. No non-code generic name or brand name has been disclosed in the provided context.